CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)	Docket No.
Applicant(s): BOTT, Michael, et al.	BMID9975US

Serial No. 09/672,265	Filing Date September 28, 2000	Examiner To Be Assigned	Group Art Unit 1632

Invention: PROCESS FOR THE RECOMBINANT PRODUCTION OF HOLO-CITRATE LYASE

(OIPE stamp: DEC 1 9 2001 PATENT & TRADEMARK OFFICE)

I hereby certify that this **Statement to Support Filing and Submision in Accordance with 37 CFR 1.821-1.825**

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

_____ **Deember 19, 2001.** _____

(Date)

_____
Rose Edwards
(Typed or Printed Name of Person Mailing Correspondence)

Rose Edwards
_____
(Signature of Person Mailing Correspondence)

EL566320281US
_____
("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

BMID 9975 US
(KW)

UNITED STATES PATENT AND TRADEMARK OFFICE

| APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/672,265	09/28/2000	Michael Bott	BMID9975US

CONFIRMATION NO. 8449

FORMALITIES LETTER

OC000000006232691

Kenneth J. Waite
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457

RECEIVED
JUL - 3 2001
PATENT DEPT.

Date Mailed: 06/27/2001

TECH CENTER 1600/2900
RECEIVED DEC 3 1 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821 (g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825 (b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

7/3/01

(Response due 8/27/01
(Final 12/27/01)

A copy of this notice __MUST__ be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY